Brilliant blue G API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Brilliant blue G is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Brilliant blue G or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Brilliant blue G API 6104-58-1?

Description:
Here you will find a list of producers, manufacturers and distributors of Brilliant blue G. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Brilliant blue G 
Synonyms:
Acid Blue 90 , C.I. Acid Blue 90 , Coomassie Brilliant Blue G  
Cas Number:
6104-58-1 
DrugBank number:
DB15594 
Unique Ingredient Identifier:
M1ZRX790SI

General Description:

Brilliant blue G, identified by CAS number 6104-58-1, is a notable compound with significant therapeutic applications. Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy. Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.

Indications:

This drug is primarily indicated for: This drug is indicated for selectively staining the internal limiting membrane (ILM). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Absorption:

The absorption characteristics of Brilliant blue G are crucial for its therapeutic efficacy: Due to the fact that this drug is administered by intravitreal injection and subsequently removed after staining, it is not expected to be significantly absorbed systemically. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Route of Elimination:

The elimination of Brilliant blue G from the body primarily occurs through: This dye is removed in a clinical setting after the surgical procedure in which it was used. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Brilliant blue G is distributed throughout the body with a volume of distribution of: This drug is administered via intravitreal injection and likely distributes only to parts of the eye. This metric indicates how extensively the drug permeates into body tissues.

Pharmacodynamics:

Brilliant blue G exerts its therapeutic effects through: Brilliant Blue G aids in ophthalmologic surgery by rendering it easier to identify the internal limiting membrane (ILM) for surgical removal. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Brilliant blue G functions by: The internal limiting membrane (ILM) is a thin and translucent structure that demarcates the transition from the retina from the vitreous body of the eye. It acts as a scaffold on which excessive tissue can grow, which results in visual distortion when it is projected onto the neighbouring retina. This causes visual loss and/or distortion. An epiretinal membrane (also known as ERM) is a fibrous type of tissue that can be found on the inner surface of the retina and occurs idiopathically, and in some cases, retinal detachment and inflammation. It is often found on the surface of the internal limiting membrane (ILM), causing visual loss and distortion. The above condition as well as the associated macular pucker or traction maculopathy can affect the ILM, contributing to visual complications. The removal of the ILM with or without vitrectomy is often a simple solution to these conditions. Brilliant Blue G specifically stains the internal limiting membrane (ILM) in the eye without staining the epiretinal membrane or the retina, allowing for easier surgical removal. The mechanism of its specific staining that is limited to the ILM is currently not fully understood. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Brilliant blue G belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine, classified under the direct parent group Phenylbenzamines. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Phenylmethylamines subclass.

Categories:

Brilliant blue G is categorized under the following therapeutic classes: Amines, Aniline Compounds, Compounds used in a research, industrial, or household setting, Indicators and Reagents, Laboratory Chemicals. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Brilliant blue G include:

  • Water Solubility: 1mg/mL

Brilliant blue G is a type of Ophthalmic Agents


Ophthalmic agents belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category specifically designed for ophthalmic applications. These agents are formulated to treat various eye conditions and disorders. Ophthalmic agents encompass a wide range of medications, including eye drops, ointments, gels, and intraocular implants.

These agents are developed to address specific therapeutic needs related to the eyes, such as reducing intraocular pressure in glaucoma, treating inflammation and infection, relieving dryness and itching, and managing allergies. They may also be used to dilate the pupils during diagnostic procedures or surgeries.

Ophthalmic agents are formulated with precise concentrations of active ingredients to ensure efficacy and safety. Common classes of ophthalmic agents include beta-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, corticosteroids, and antihistamines.

When administering ophthalmic agents, it is crucial to follow proper application techniques to ensure optimal drug delivery and minimize side effects. Eye drops, for example, are typically applied as a gentle instillation into the conjunctival sac, while ointments are applied along the lower eyelid.

These pharmaceutical API ophthalmic agents undergo rigorous quality control and regulatory scrutiny to meet industry standards and ensure patient safety. Manufacturers must comply with Good Manufacturing Practices (GMP) and adhere to stringent quality assurance protocols.

Overall, ophthalmic agents play a vital role in the management and treatment of various eye conditions, providing patients with targeted relief and improving ocular health. It is important to consult with a healthcare professional to determine the appropriate ophthalmic agent for individual needs and to receive proper guidance on usage and potential side effects.